Skip to main content

Table 3 Prognostic factors of OS

From: Comparison of the outcomes between sorafenib and lenvatinib as the first-line systemic treatment for HBV-associated hepatocellular carcinoma: a propensity score matching analysis

 

Univariable

Multivariable

HR

95% CI

p-value

aHR

95% CI

p-value

Age > 60 yr

0.78

0.57–1.07

0.125

   

Male

1.04

0.63–1.72

0.886

   

PIVKA II > 250 mAU/mL

1.77

1.27–2.46

0.001

   

AFP > 200 ng/mL

2.11

1.54–2.89

 < 0.001

1.73

1.23–2.45

0.002

Total bilirubin

1.20

1.11–1.29

 < 0.001

1.18

1.09–1.29

 < 0.001

Albumin

0.62

0.47–0.82

0.001

   

ALT

1.01

1.00–1.01

0.003

1.00

1.00–1.01

0.039

AST

1.00

1.00–1.01

 < 0.001

   

PT

2.29

1.40–3.74

0.001

   

Presence of ascites

1.97

1.41–2.77

 < 0.001

   

ECOG 1 (vs 0)

2.09

1.50–2.90

 < 0.001

1.98

1.41–2.77

 < 0.001

Child B, C (vs A)

1.88

1.32–2.66

 < 0.001

   

BCLC stage C, D (vs B)

1.72

1.03–2.89

0.039

1.77

1.01–3.10

0.045

Tumor size

1.01

1.01–1.01

 < 0.001

1.01

1.00–1.01

 < 0.001

Extrahepatic metastasis

0.96

0.69–1.33

0.809

   

Portal vein thrombosis

1.53

1.13–2.09

0.007

   

Biliary invasion

1.44

0.80–2.60

0.223

   

Lenvatinib (vs sorafenib)

1.41

0.96–2.08

0.077

1.36

0.89–2.07

0.154

Previous anti-HCC treatment

0.46

0.31–0.68

 < 0.001

   
  1. Multivariable analysis was performed using variables with p value under 0.05 at univariable analysis
  2. HR, hazard ratio; aHR, adjusted hazard ratio; CI, confidence interval; PIVKA, protein induced by vitamin K absence or antagonists-II; AFP, alpha-fetoprotein; ALT, alanine aminotransferase; AST, aspartate aminotransferase; PT, prothrombin time; ECOG, Eastern Cooperative Oncology Group; BCLC, Barcelona Clinic Liver Cancer